|
NRG Oncology/RTOG 9601, a phase III trial in prostate cancer patients: Anti-androgen therapy (AAT) with bicalutamide during and after salvage radiation therapy (RT) following radical prostatectomy (RP) and an elevated PSA. |
|
|
Stock and Other Ownership Interests - Pfizer; Pfizer (I) |
|
|
Research Funding - Genentech/Roche (Inst) |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Sanofi |
|
|
No Relationships to Disclose |
|
|
Stock and Other Ownership Interests - Medtronic; United Health Group |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Leadership - PFS Genomics |
Stock and Other Ownership Interests - PFS Genomics |
Consulting or Advisory Role - Celgene; GenomeDx; Medivation/Astellas |
Research Funding - Celgene; Varian Medical Systems |
Patents, Royalties, Other Intellectual Property - I helped develop a molecular signature to predict radiation resistance in breast cancer, and this signature was patented by the University of Michigan, my employer. It is in the process of being licensed to PFS Genomics, a company that I helped found. (Inst) |
|
|
No Relationships to Disclose |
|
|
|
Consulting or Advisory Role - Seagen (Inst) |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Employment - 21st Century Oncology |
|
|
Consulting or Advisory Role - AstraZeneca; Bayer; Eviti; Janssen; Medivation/Astellas |
Research Funding - Myriad Genetics |
Other Relationship - Caribou Publishing |